India’s Aurobindo buys Sandoz US assets from Novartis
Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment.
This content was published on
2 minutes
A possible performance-related payment of $100 million could be added to the purchase price, the Swiss AWP financial news agency reported.
The divested business generated sales of $600 million in the first half of 2018. It includes approximately 300 products and development projects.
A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were still for sale.
750 employees affected
The production facilities in Wilson, North Carolina, as well as in Hicksville and Melville, New York, will also be transferred to Aurobindo.
In this context, approximately 750 employees and the sales force of the dermatology business PharmaDerm will be transferred to the Indian company upon completion of the transaction.
Novartis said the transaction is expected to close during 2019.
Focus on complex generics
Sandoz will focus instead on complex generics, value-added medicines and biosimilars.
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. “With this transaction, we are focusing our business,” Sandoz CEO Richard Francis was quoted as saying.
The Sandoz portfolio will remain “strong” even after the transaction, according to the company statement. It includes injectables, respiratory products and ophthalmics.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis chief hints at job cuts in Switzerland
This content was published on
The president of pharmaceutical giant Novartis has announced job cuts in an interview with Swiss newspaper NZZ am Sonntag.
This content was published on
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time…
Eye on the Multinationals: Your questions become our stories
This content was published on
Do you work for or would like to work for a multinational company? Are you concerned about the impact of multinational companies at home and abroad?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.